Pfizer Adjusts Executive Compensation Plans

Ticker: PFE · Form: 8-K · Filed: 2024-07-10T00:00:00.000Z

Sentiment: neutral

Topics: executive-compensation, incentive-plan, board-of-directors

Related Tickers: PFE

TL;DR

Pfizer just tweaked its executive pay plans, effective July 9th. Expect more details soon.

AI Summary

On July 9, 2024, Pfizer Inc. announced changes to its executive compensation program. The company's Compensation Committee of the Board of Directors approved amendments to the 2023 Long-Term Incentive Plan and the 2024 Annual Incentive Plan, impacting key executive officers. These changes are effective as of July 9, 2024.

Why It Matters

Changes to executive compensation can signal shifts in company strategy or performance expectations, potentially influencing investor sentiment and future stock performance.

Risk Assessment

Risk Level: low — This filing concerns routine executive compensation adjustments and does not indicate significant financial distress or strategic shifts.

Key Players & Entities

FAQ

What specific amendments were made to the 2023 Long-Term Incentive Plan and the 2024 Annual Incentive Plan?

The filing states that the Compensation Committee approved amendments to these plans, but does not detail the specific changes within this current report.

Who are the key executive officers affected by these compensation changes?

The filing indicates that key executive officers are impacted, but does not name them specifically in this report.

What is the effective date of these compensation plan amendments?

The amendments to the executive compensation plans are effective as of July 9, 2024.

What is the purpose of these amendments to the incentive plans?

The filing does not explicitly state the purpose of the amendments, but such changes are typically made to align executive compensation with company performance and strategic goals.

Where can I find more detailed information about the amended compensation plans?

More detailed information regarding the specific amendments would likely be found in subsequent filings or exhibits to this Form 8-K, or in the company's proxy statement.

From the Filing

0000078003-24-000130.txt : 20240710 0000078003-24-000130.hdr.sgml : 20240710 20240710161100 ACCESSION NUMBER: 0000078003-24-000130 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240709 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240710 DATE AS OF CHANGE: 20240710 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 241110073 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 pfe-20240709.htm 8-K pfe-20240709 0000078003 false 0000078003 2024-07-09 2024-07-09 0000078003 us-gaap:CommonStockMember 2024-07-09 2024-07-09 0000078003 pfe:NotesDue20271.000Member 2024-07-09 2024-07-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 9, 2024 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 9, 2024, Pfizer Inc. (the "Company") announced that it is beginning the process of finding a successor for Dr. Mikael Dolsten, the Company’s Chief Scientific Officer and President, Pfizer Research & Development after his more than 15-year distinguished career with the Company. The Company has initiated an external search for a new Chief Scientific Off

View on Read The Filing